Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a ...

Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a major target of cancer immunotherapy. Unfortunately, drugs that target it do ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

Promega Corporation has introduced a new platform designed to help drug discovery scientists study some of the most challenging protein targets in living cells, enabling earlier and more reliable ...

BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...

Healio: Reshmi Parameswaran, assistant professor at the School of Medicine, discussed research into BAFF ligand-based CAR T-cell therapy. “Given my previous experience with BAFF receptor antibodies as ...

The behaviour of a receptor protein can be influenced by the presence of certain lipids in the membrane it is embedded in.

Bevacizumab in combination with chemotherapy for treating patients with advanced RET+ non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...